Loading...
Emerging therapies in advanced hepatocellular carcinoma
BACKGROUND: Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this article, we will review the newer approved and promising agents in the treatment o...
Na minha lista:
| Udgivet i: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076403/ https://ncbi.nlm.nih.gov/pubmed/30087805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0109-6 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|